Welcome to our dedicated page for Chemomab Therapeutics SEC filings (Ticker: CMMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Chemomab Therapeutics Ltd. (CMMB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Chemomab files annual reports on Form 20-F and current reports on Form 6-K, which together offer insight into its clinical-stage biotechnology business focused on nebokitug, a monoclonal antibody targeting CCL24 in fibro-inflammatory diseases such as primary sclerosing cholangitis (PSC).
Through its Form 6-K submissions, Chemomab furnishes press releases, unaudited condensed consolidated financial statements, and management’s discussion and analysis for interim periods. These filings detail research and development spending, general and administrative expenses, cash resources and liquidity outlook, as well as narrative updates on the nebokitug development program, including the Phase 2 SPRING trial in PSC and preparations for a planned Phase 3 registration study. Certain 6-Ks also incorporate by reference financial tables, interactive data files and other exhibits into the company’s shelf registration statements and equity compensation plans.
Investors can also review filings that describe capital markets activities, such as at-the-market (ATM) equity offering programs and changes to the ratio of American Depositary Shares (ADSs) to ordinary shares, which effectively function as reverse ADS splits. These documents outline the terms under which Chemomab may sell ADSs, the role of its sales agent, and related legal opinions. Additional 6-Ks report outcomes of shareholder meetings, including director elections, equity awards and auditor appointments.
For those analyzing Chemomab’s governance and regulatory status, the filings page is a central source for information on registration statements on Form F-3 and Form S-8, as well as references to risk factor discussions in the company’s Form 20-F. While detailed clinical protocols and scientific data are often summarized in attached press releases, the SEC filings frame how these developments fit into Chemomab’s overall business, financing strategy and regulatory obligations.
On Stock Titan, these documents are complemented by AI-powered tools that can summarize lengthy filings, highlight key sections related to nebokitug’s PSC program, and help users quickly locate information on topics such as liquidity, share structure changes, or the incorporation by reference of new disclosures into existing registration statements.
Chemomab Therapeutics Ltd. has called its Annual General Meeting for April 28, 2026 in Ramat Gan, Israel, asking shareholders to vote on four key proposals. Shareholders will be asked to re-elect two Class II directors, Neil Cohen and Claude Nicaise, for terms running to the 2029 meeting.
Investors are also being asked to approve a refreshed compensation policy for executive officers and directors, which the company describes as largely similar to the existing policy with some updates. Another proposal would increase authorized share capital by 8,000,000,000 ordinary shares, bringing total authorization to 12,650,000,000 ordinary shares of no par value.
The final proposal seeks to reappoint Somekh Chaikin, a member firm of KPMG International, as independent auditors for the year ending December 31, 2026, with the board authorized to set fees. As of March 19, 2026, 7,200,387 American Depositary Shares were outstanding, each representing 80 ordinary shares and carrying one vote at the meeting.
Chemomab Therapeutics reported 2025 results showing progress on both its nebokitug program and its finances. Following strong Phase 2 SPRING data in primary sclerosing cholangitis (PSC), the company completed a successful FDA End-of-Phase 2 meeting and reached alignment on a single Phase 3 registration trial design using a clinical event-driven composite endpoint.
For the year ended December 31, 2025, Chemomab recorded a net loss of 8,995 thousand, an improvement from 13,945 thousand in 2024, as total operating expenses declined to 9,567 thousand from 14,739 thousand. Research and development expenses fell to 5,833 thousand and general and administrative expenses were 3,734 thousand. As of December 31, 2025, total assets were 13,812 thousand and shareholders’ equity was 12,334 thousand, supported by 575,381,320 Ordinary Shares outstanding.
Peter Thiel and Rivendell Investments 2017-9 LLC report a 4.6% passive stake in Chemomab Therapeutics Ltd. on Schedule 13G/A. They beneficially own 22,631,200 ordinary shares as of December 31, 2025, based on 492,409,320 shares outstanding as of September 30, 2025.
The position is held through American Depositary Shares and a warrant: 22,170,160 ordinary shares represented by 277,127 ADSs and 461,040 ordinary shares represented by 5,763 ADSs issuable upon warrant exercise. Each ADS represents 80 ordinary shares. The filers state the securities are not held to change or influence control.
Chemomab Therapeutics Ltd. disclosed that individual investor Erik Otto, a Canadian citizen, has filed an amended Schedule 13G reporting a significant ownership stake in the company’s American Depositary Shares (ADSs).
Otto reports beneficial ownership of 385,000 ADSs, representing 6.3% of Chemomab’s ADSs, based on 6,155,117 ADSs outstanding as of November 20, 2025, as provided by the company. He has sole voting and sole dispositive power over all of these ADSs, meaning he alone can vote and decide when to sell them.
The filing is made on Schedule 13G/A, which is typically used for passive investors. Otto certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Chemomab, and are not held in connection with any control-seeking transaction.
Chemomab Therapeutics Ltd. filed a Form 6-K as a foreign private issuer to furnish a press release titled “Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Corporate Update.” The press release is attached as Exhibit 99.1.
The company states that Exhibit 99.1 is incorporated by reference into its existing registration statements on Form F-3 and Form S-8. The report is signed on behalf of Chemomab by Chief Financial Officer Sigal Fattal.
Chemomab Therapeutics Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares. Each ADS, which currently represents twenty ordinary shares, will represent eighty ordinary shares after the change, effectively a one-for-four reverse ADS split for ADS holders. The ratio change will take effect on August 26, 2025.
The Company’s ADSs will continue to trade on the Nasdaq Capital Market under the ticker CMMB, with a new CUSIP number of 16385C203. The Bank of New York Mellon, as depositary bank, will exchange every four existing ADSs for one new ADS on the effective date. No new ADSs will be issued in connection with this adjustment, and any fractional ADS positions will be aggregated, sold by the depositary, and the net cash proceeds distributed to affected ADS holders.
Chemomab Therapeutics Ltd. furnished a Form 6-K for August 2025 reporting the inclusion of three exhibits related to its second quarter of 2025. The filing states it includes unaudited condensed consolidated financial statements for the three and six months ended June 30, 2025, the companys Managements Discussion and Analysis of financial condition and results of operations for those periods, and a press release dated August 14, 2025 titled "Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update." The exhibits (99.1, 99.2, 99.3) and interactive financial data files are designated and will be deemed incorporated by reference into specified Form F-3 and Form S-8 registration statements. The report is signed by the Chief Financial Officer, Sigal Fattal.
Chemomab Therapeutics Ltd. has a disclosed beneficial owner, Erik Otto, who holds 1,690,000 American Depositary Shares (ADSs), representing 8.1% of the ADS class. Each ADS represents twenty ordinary shares.
Mr. Otto reports sole voting and sole dispositive power over these ADSs and certifies the holdings were not acquired to change or influence control of the issuer. The ownership percentage is stated based on the issuer's count of outstanding ADSs.
Morgan Stanley and subsidiary file Schedule 13G/A (Amendment 1) for Chemomab Therapeutics (CMMB) covering an ownership change effective 07/31/2025.
- Morgan Stanley reports 13,213,260 ordinary shares/ADS held with shared voting & dispositive power, equal to 3.2 % of Chemomab’s outstanding class.
- Morgan Stanley & Co. LLC reports 9,275,360 shares (shared voting & dispositive power) representing 2.2 % of the class.
- Both filers certify that they have ceased to be beneficial owners of more than 5 % of the issuer’s equity, triggering this amendment.
- Reporting persons are classified as HC/CO (holding company) and BD/CO (broker-dealer) under Item 3.
- No other persons have sole voting or dispositive authority; all powers are shared within the Morgan Stanley reporting units.
- The filing includes a Joint Filing Agreement (Ex. 99.1) and Item 7 subsidiary information (Ex. 99.2).
The amendment signals a reduction of Morgan Stanley’s aggregate position below the 5 % regulatory threshold, though the group still retains a meaningful minority stake.
Schedule 13G filing dated 06/30/2025 shows Morgan Stanley and subsidiary Morgan Stanley & Co. LLC have exceeded the 5 % threshold in Chemomab Therapeutics Ltd. (CMMB).
- Morgan Stanley reports 32,282,680 ordinary shares/ADS, representing 8.4 % of the outstanding class.
- Morgan Stanley & Co. LLC separately holds 28,786,680 shares or 7.5 %.
- Both entities report shared voting and dispositive power; no sole authority is listed.
- Filed under Rule 13d-1(b) as a broker-dealer/holding company, signalling a passive investment rather than a control bid.
- Cover pages classify the parent as “HC, CO” and the subsidiary as “BD, CO.”
- Signatures by authorised signatory Christopher O’Hara are dated 08/07/2025.
The disclosure increases institutional visibility and liquidity for CMMB but contains no operational or strategic changes.